GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rezolute Inc (NAS:RZLT) » Definitions » Cyclically Adjusted PB Ratio

Rezolute (Rezolute) Cyclically Adjusted PB Ratio : 0.53 (As of May. 24, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Rezolute Cyclically Adjusted PB Ratio?

As of today (2024-05-24), Rezolute's current share price is $3.215. Rezolute's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $6.12. Rezolute's Cyclically Adjusted PB Ratio for today is 0.53.

The historical rank and industry rank for Rezolute's Cyclically Adjusted PB Ratio or its related term are showing as below:

RZLT' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0.56
Current: 0.46

During the past years, Rezolute's highest Cyclically Adjusted PB Ratio was 0.56. The lowest was 0.00. And the median was 0.00.

RZLT's Cyclically Adjusted PB Ratio is ranked better than
75% of 652 companies
in the Biotechnology industry
Industry Median: 1.74 vs RZLT: 0.46

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Rezolute's adjusted book value per share data for the three months ended in Mar. 2024 was $1.766. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $6.12 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Rezolute Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Rezolute's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rezolute Cyclically Adjusted PB Ratio Chart

Rezolute Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 20.75 2.02 0.50

Rezolute Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.69 0.50 0.25 0.16 0.42

Competitive Comparison of Rezolute's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Rezolute's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rezolute's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rezolute's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Rezolute's Cyclically Adjusted PB Ratio falls into.



Rezolute Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Rezolute's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=3.215/6.12
=0.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rezolute's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Rezolute's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.766/131.7762*131.7762
=1.766

Current CPI (Mar. 2024) = 131.7762.

Rezolute Quarterly Data

Book Value per Share CPI Adj_Book
201406 17.707 100.560 23.204
201409 13.775 100.428 18.075
201412 17.763 99.070 23.627
201503 20.616 99.621 27.270
201506 18.601 100.684 24.345
201509 13.884 100.392 18.224
201512 7.762 99.792 10.250
201603 2.299 100.470 3.015
201606 12.493 101.688 16.190
201609 10.919 101.861 14.126
201612 9.686 101.863 12.530
201703 9.306 102.862 11.922
201706 8.662 103.349 11.045
201709 7.264 104.136 9.192
201712 3.516 104.011 4.455
201803 0.493 105.290 0.617
201806 -3.186 106.317 -3.949
201809 -5.182 106.507 -6.411
201812 -7.911 105.998 -9.835
201903 -21.409 107.251 -26.305
201906 0.416 108.070 0.507
201909 3.515 108.329 4.276
201912 2.504 108.420 3.043
202003 1.760 108.902 2.130
202006 1.255 108.767 1.520
202009 0.747 109.815 0.896
202012 4.297 109.897 5.152
202103 3.488 111.754 4.113
202106 3.125 114.631 3.592
202109 2.495 115.734 2.841
202112 4.003 117.630 4.484
202203 3.337 121.301 3.625
202206 4.451 125.017 4.692
202209 4.157 125.227 4.374
202212 3.836 125.222 4.037
202303 3.457 127.348 3.577
202306 3.155 128.729 3.230
202309 2.812 129.860 2.854
202312 2.315 129.419 2.357
202403 1.766 131.776 1.766

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Rezolute  (NAS:RZLT) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Rezolute Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Rezolute's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Rezolute (Rezolute) Business Description

Industry
Traded in Other Exchanges
N/A
Address
275 Shoreline Drive, Suite 500, Redwood City, CA, USA, 94065
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.
Executives
Brian Kenneth Roberts officer: Chief Medical Officer C/O REZOLUTE, INC., 201 REDWOOD SHORES PARKWAY, SUITE 315, REDWOOD CITY CA 94065
Gil M Labrucherie director 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Wladimir Hogenhuis director 60 LEVERONI COURT, NOVATO CA 94949
Nerissa Kreher director C/O AVROBIO, INC., ONE KENDALL SQ., BLDG. 300, STE. 201, CAMBRIDGE MA 02139
Handok, Inc. 10 percent owner 132, TEHERAN-RO, GANGNAM GU, SOUL M5 06235
Philippe Fauchet director C/O REZOLUTE, INC., 201 REDWOOD SHORES PARKWAY, SUITE 315, REDWOOD CITY CA 94065
Junghee Lim director C/O REZOLUTE, INC., 201 REDWOOD SHORE'S PARKWAY, SUITE 315, REDWOOD CITY CA 94065
Genexine Inc. 10 percent owner 700 DAEWANGPANGYO-RO, KOREA PARKBLDG. B, BUNDANG-GU, SEONGNAM-SI, GYEONGGI-DO M5 13488
Seline E. Miller officer: VP Finance & CAO C/O REZOLUTE, INC., 1450 INFINITE DRIVE, LOUISVILLE CO 80027
Young-jin Kim director 49, BONGEUNSA-RO 49-GIL, GANGNAM-GU, SEOUL M5 06100
Young Chul Sung director 101DONG 404HO, PARKTOWER APT. 69, SEOBINGGO-RO, YONGSAN-GU, SEOUL M5 04385
Keith A. Vendola officer: Chief Financial Officer 111 LIVORNO WAY, REDWOOD CITY CA 94065
Xoma Corp 10 percent owner 2200 POWELL STREET, SUITE 310, EMERYVILLE CA 94608
David F Welch director C/O INFINERA CORPORATION, 140 CASPIAN COURT, SUNNYVALE CA 94089
Morgan Fields officer: Chief Accounting Officer 890 SANTA CRUZ AVE., MENLO PARK CA 94025